Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Payer Insights: RA : Update Bulletin [May 2017]

Product Code:
April Date:
May 2017

This edition presents payer views on recent developments in the rheumatoid arthritis (RA) market. Topics include; recent positive opinion from the European Medicines Agency (EMA) for Regeneron/Sanofi’s Kevzara (sarilumab); recent approvals of biosimilar Enbrel and biosimilar Humira in the EU; and Eli Lilly/Incyte’s Olumiant (baricitinib) gaining marketing authorisation in the EU.

Business Questions:

  • How do payers intend to cover sarilumab? Will there be any restrictions?
  • Is sarilumab likely to be utilised as a first or second-line therapy?
  • What factors will determine the incorporation of sarilumab in formularies? What role will drug pricing and treatment guidelines play?
  • Will biosimilars of Enbrel and Humira capture market share from branded anti-TNFs?
  • Will the availability of biosimilar anti-TNFs improve patient access to RA treatment?
  • What role will payers play in switching patients to biosimilar anti-TNFs?
  • What patient subset will be targeted for switching to biosimilar anti-TNFs?
  • On what factors will the uptake of biosimilars be dependent on?
  • Will payers prefer biosimilars of Enbrel over biosimilars of Humira?
  • How are biosimilars of Remicade viewed by payers? 
  • Are payers surprised that baricitinib was declined approval in the US, but not in the EU?
  • How important will discounts on baricitinib be for making reimbursement decisions?
  • Will the RA treatment paradigm shift towards oral and/or biosimilar agents?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.


All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved